ABTNYSEPharmaceutical PreparationsFiscal year ends December 31

ABBOTT LABORATORIES

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$104.06−0.83 (-0.79%)

Close on Oct 19, 2026

Market cap: $181.37B
P/E (TTM): 33.5
Dividend yield: 2.31%

ABBOTT LABORATORIES income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	44,328	41,950	40,109	43,653	43,075	34,608	31,904	30,578	27,390	20,853	20,405	20,247	19,657	19,050	21,407	35,167	30,765	29,528	25,914
Cost of Revenue	19,319	18,706	17,975	19,142	18,537	15,003	13,231	12,706	12,409	9,094	8,747	9,218	9,193	8,899	10,017	14,665	13,209	12,612	11,422
Gross Profit	25,009	23,244	22,134	24,511	24,538	19,605	18,673	17,872	14,981	11,759	11,658	11,029	10,464	10,151	11,390	20,502	17,555	16,916	14,492
Research & Development	2,942	2,844	2,741	2,888	2,742	2,420	2,440	2,300	2,260	1,447	1,405	1,345	1,371	1,461	1,512	3,724	2,744	2,689	2,506
Selling, General & Admin	12,332	11,697	10,949	11,248	11,324	9,696	9,765	9,744	9,182	6,736	6,785	6,530	6,372	6,735	7,365	10,376	8,406	8,436	7,408
Total Costs & Expenses	36,275	35,125	33,631	35,291	34,650	29,251	27,372	26,928	25,826	17,827	17,538	17,648	17,524	17,690	19,778	29,079	24,529	23,834	21,336
Operating Income	8,053	6,825	6,478	8,362	8,425	5,357	4,532	3,650	1,564	3,026	2,867	2,599	2,133	1,360	1,629	6,088	6,236	5,694	4,579
Interest Expense	493	559	637	558	533	546	670	826	904	431	163	150	145	320	359	553	520	528	593
Interest & Investment Income	308	344	385	183	43	46	94	105	124	99	105	77	67	59	65	105	138	201	137
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	119	498
Other Non-Operating Income	548	376	479	321	277	103	191	139	1,413	-786	281	-14	32	1.00	-119	62	1,375	455	-136
Merger & Restructuring Charges	–	–	–	–	–	36	66	28	–	–	–	–	–	395	25	13	47	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	–	–	0	–	0	0	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	1,163	25	2,840	–	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	287	–	–
Pretax Income	8,466	7,013	6,664	8,306	8,211	4,968	4,077	2,873	2,231	1,413	3,183	2,518	2,041	-220	1,236	5,713	7,194	–	–
Income Tax Expense	1,942	-6,389	941	1,373	1,140	497	390	539	1,878	350	577	797	53	-457	110	1,087	1,448	1,122	863
Income from Continuing Operations	–	–	–	6,933	7,071	4,471	3,687	2,334	353	1,063	2,606	1,721	1,988	237	1,126	4,626	5,746	4,734	3,606
Income from Discontinued Operations	–	–	–	0	0	24	–	34	124	337	1,817	563	588	5,726	3,602	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	7,071	4,495	3,687	2,368	477	1,400	4,423	–	–	–	–	4,626	5,746	4,881	3,606
Net Income	6,524	13,402	5,723	6,933	7,071	4,495	3,687	2,368	477	1,400	4,423	2,284	2,576	5,963	4,728	–	–	–	–
Net Income to Common	6,500	13,400	5,700	6,905	7,042	4,473	3,666	2,353	468	1,393	4,403	2,273	2,558	5,917	4,714	4,626	5,746	–	–
EPS (Basic)(per share)	3.73	7.67	3.28	3.94	3.97	2.52	2.07	1.34	0.27	0.94	2.94	1.50	1.64	3.76	3.03	2.98	3.71	3.16	2.34
EPS (Diluted)(per share)	3.72	7.64	3.26	3.91	3.94	2.50	2.06	1.33	0.27	0.94	2.92	1.49	1.62	3.72	3.01	2.96	3.69	3.12	2.31
Shares Outstanding (Basic, Weighted)(shares)	1,741	1,740	1,740	1,753	1,775	1,773	1,768	1,758	1,740	1,477	1,496	1,516	1,558	1,575	1,557	1,546	1,547	1,545	1,543
Shares Outstanding (Diluted, Weighted)(shares)	1,748	1,748	1,749	1,764	1,789	1,786	1,781	1,770	1,749	1,483	1,506	1,527	1,574	1,592	1,567	1,556	1,555	1,561	1,560
Dividend per Share(per share)	2.40	2.24	2.08	1.92	–	–	–	–	–	–	–	–	–	–	1.92	1.76	1.60	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 56.6%
Operating margin: 15.8%
Net margin: 11.6%
Return on equity, FY2025: 13.1%

Financial strength

Current ratio: 1.38
Debt to equity: 0.64
Debt to assets: 29.9%
Cash to current liabilities: 28.7%

Valuation

P/E ratio: 33.5
Price to sales: 3.89
Price to book: 3.55
Dividend yield: 2.31%